We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
7.50 | 1.65% | 462.50 | 455.00 | 470.00 | 462.50 | 455.00 | 455.00 | 41,048 | 14:06:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 49.15 | 219.23M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/2/2018 13:38 | Ecomed SA/NV @EcomedSANV Tristel Duo Ultrasound wordt Tristel Duo ULT: enkel een nieuw jasje, aan de inhoud en de werking verandert niets! @TristelGlobal #highleveldes infectie #chloordioxide #30Seconden #infectiepreventie Translated from Dutch by Microsoft Tristel Duo Ultrasound becomes Tristel duo ULT: Just a new jacket, to the content and operation nothing changes! @TristelGlobal #highleveldesinfecti Seconden #infectiepreventie - where are they going with these name changes? - knock off the ULT > Tristel Duo? | piedro | |
16/2/2018 10:36 | Thank you for your offer Glaws2. I do have some questions on product development ... - how much is being spent on product development and marketing? - what percentage reaches the market? - and of the new products, how many are successful? The reason for asking is that ... Known products under development: 'Revolver' is no longer mentioned and now there is 'Puffin' Products launched but seemingly discontinued: Shine - Washer disinfector Legion - disinfecting and descaling foam Dental products: Dentel Duo / Dentel 100 / Dentel 5 Baby Products: Protect sporicidal foam / Protect bactericidal wipes Tristel Life: 5 / Foam / Wipes system | piedro | |
16/2/2018 09:39 | Piedro Any idea why so much interest in tristel from Bolivia? biggest number of non UK visits to the site | cameronm | |
16/2/2018 07:05 | It's quiet at the moment as we are all waiting for next week's interims. I'm going to the presentation of you want any questions asked Piedro. | glaws2 | |
15/2/2018 10:17 | FYI, You may have noticed the "Visitors counter" {by FlagCounter.com} in the header. - I find it useful by reason of the fact that although I am sometimes the only person contributing, there have been for example, 670 odd pageviews in the last 30 days. - from all parts - please feel free to express your opinions, for better or for worse; I have it on good authority that members of the company do look in from time to time. Best regards,:-) Piedro | piedro | |
13/2/2018 14:06 | The original 'Research Article' is well worth reading being well balanced regarding the results and also mentions the economics of each method - there were 5 positive cultures found on post-decontamination swabs, 2 of which were from non-contaminated swabs !! - which somewhat reduces the credibility of the study IMO "We believe the positive cultures post decontamination are likely due to improper handling of the nasoendoscopes post decontamination rather than a result of inadequate disinfection." | piedro | |
13/2/2018 13:07 | Original Research Article Flexible nasoendoscopy decontamination: a comparison between Rapicide and Tristel wipes, a prospective cohort study Yijin Jereme Gan, Alex Mathews, Phua Chuqin, Ivan Khoo, David Loke | piedro | |
13/2/2018 12:11 | The post-decontamination swab culture results were four positive culture swabs for those disinfected with Tristel Wipes and one positive culture swab for Rapicide cohort. The efficacy of Rapicide was 98.8% compared to 94.7% for Tristel. After statistical analysis, the difference between either was not considered to be statistically significant. The study also noted that the positive cultures post-decontamination were likely due to improper handling of the nasoendoscopes rather than a result of inadequate disinfection. In conclusion, the study validated the efficacy of Tristel Wipes as a comparable alternative to peracetic acid-based disinfectants for flexible nasoendoscopes. The study also concluded that Tristel is a more convenient, faster, more portable and more ergonomic alternative to Rapicide. - wonderful thing 'statistical analysis' !!! - 4 vs 1 = no difference | piedro | |
13/2/2018 11:56 | Found on twitter ... Tristel Global@TristelGlobal Introducing Tristel Science First paper: Study concludes that chlorinedioxide wipes have equivalent efficacy to a world-leading peraceticacid high-level disinfectant and provide significant other advantages to hospitals. - it is as though they did not want this to been seen! - and take us for idiots - website becoming convoluted again AIMHO, BWDIK ... | piedro | |
10/2/2018 12:23 | I'm looking forward to Q2 results in 10 days time and hoping for positive news regards their progress with the EPA application for approval although it may be a little early for that since the update in December. The interim dividend announcement should also be interesting; I expect a small increase but that may be optimistic if the company is seeking to build a big war chest to exploit US opportunities when (if?) that comes. I'm considering topping up ahead of results, especially if there is another dip down. Any similar thoughts out there? | zimbtrader | |
09/2/2018 10:21 | Glaws2 - thank you, I have found the reference I use ShareScope but find it quite inadequate for Major Holdings and Directors Dealings from the Annual Reports: ..Date.........Share 30-09-12.... 1,388,515... 3.47% 30-09-16.... 1,315,638... 3.11% 30-06-17.... 1,936,122... 4.53% and the latest RNS 07-02-18.... 2,149,337... 5.00% | piedro | |
09/2/2018 06:09 | Piedro - I lifted the information from Sharepad | glaws2 | |
08/2/2018 14:59 | Thank you Glaws. I do not have any record of a previous Investec holding - can you tell me when it happened ? | piedro | |
08/2/2018 14:28 | Investec have gone upto 5% - previously they had 4.5% | glaws2 | |
08/2/2018 14:21 | Investec Wealth & Investment Limited bought 5%. Any significance? | ashehzi | |
25/1/2018 07:57 | Vesismin Health @Vesismin Desinfección de Alto Nivel de sondas invasivas: - in Spanish but worth a read | piedro | |
24/1/2018 07:09 | Today's RNS - Study shows comparable efficacy of Tristel Wipes Tristel's chlorine dioxide wipes are validated as a viable alternative to peracetic acid disinfectants for the high-level disinfection of flexible nasendoscopes Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that a study conducted at the Khoo Tech Puat Hospital, Singapore, has concluded that the Tristel Wipe has comparable efficacy to a world leading peracetic acid high-level disinfectant (Rapicide; Cantel Medical, New Jersey, USA), and provides significant other advantages to a hospital. The study has been published in the International Journal of Otorhinolaryngology and Head and Neck Surgery (Gan YJ et al. Int J. Otorhinolaryngol Head Neck Surg. 2018 Jan; 4(1):18-23). Cantel is one of the world's largest dedicated infection prevention companies quoted on the NYSE. The study took place in the Ear, Nose and Throat clinic during 2014. One hundred patients volunteered to participate and for each endoscopic examination one nasendoscope disinfected by Rapicide and one nasendoscope disinfected by a Tristel Wipe was used to scope each nasal passage of the patient. From swabbing each nasendoscope pre and post disinfection to reveal evidence of bacterial contamination the study concludes that Rapicide and the Tristel Wipe are statistically equivalent in terms of efficacy. In addition to being comparable with Rapicide the study identifies other significant advantages of the Tristel Wipe. These benefits are rapid turnaround of the nasendoscope (2-3 minutes for Tristel versus 20 minutes for Rapicide) which means the clinic can see more patients in a day with fewer nasendoscopes; Tristel's safety from a health standpoint, and the Tristel Wipe's portability which means that it can be easily taken to the emergency department or to the wards. This is important as even though most ENT departments are out-patient areas, frequently in-patients carry MRSA, vancomycin-resistant Enterococci (VRE), and even tuberculosis, and need to have a nasendoscopy. The Tristel Wipe can easily be taken to them to enable the examination. The Tristel Wipes System is a unique, patented decontamination method for non-lumened endoscopes and ultrasound probes. It has been a very significant sales success for the Company globally. Worldwide sales of the Wipes System in the financial year ending June 2017 were £11.5m. Paul Swinney, CEO, comments: "We are pleased to see the publication in a peer-reviewed journal of yet another study comparing our Wipe with a leading peracetic acid high-level disinfectant - Cantel's Rapicide product. Peracetic acid is the most widely used high-level disinfectant chemistry in Europe and probably the United States also. The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods. These advantages are the level and speed of kill and the capability of our Wipe System to be deployed anywhere within a healthcare setting without the need for power, water and space. This is the thirty first peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our Company's key strengths." | metis20 | |
17/1/2018 10:00 | Sorry Piedro - the comment was in jest as I know full well Liz (who I have met many times) is the board FD; I just thought Oakley was inflating his role. | glaws2 | |
17/1/2018 09:39 | Liz Dixon - Chief Financial Officer Joined in July 2007 Glaws2, - Paul Oakley may be Finance Director but not a member of the BoD - from website Board of Directors Francisco Soler Paul Swinney Liz Dixon Paul Barnes David Orr Tom Jenkins | piedro | |
17/1/2018 09:08 | Paul Oakley - Finance Director at Tristel Solutions and Group Head of Finance Joined in June 2010 - I have been involved in and been the lead on operating system implementations. The most recent, being the lead on a group wide roll-out of SAP Business One, on HANA, the roll-out included the UK, Germany, New Zealand, Hong Kong and China. - Through my roles I have produced and now oversee the production of monthly management accounts but also monthly business wide reporting. Cashflow, Treasury management, payroll and HR are overseen by myself and the I.T department reports. The production of year end accounts and seeing them through successful audits are my responsibility also [Source: LinkedIn] | piedro | |
17/1/2018 08:52 | Tim Newton - Head of Global IT & Systems at Tristel plc Joined in August 2014 Manage and maintain all aspects of the IT for over 100 users across 4 branches globally which include Newmarket, Berlin, Shanghai, Tauranga (New Zealand). • Worldwide roll out of SAP Business One Hana (ERP system) for 4 branches with zero downtime and impact to the daily running of the business. ... ... [Source: LinkedIn] - it has taken him 3½ yrs to roll out the system !! | piedro | |
17/1/2018 07:43 | New finance director there ! | glaws2 | |
17/1/2018 00:49 | It's nothing to do with the share price or the accounts It's about what makes the company 'tick' :-) | piedro | |
17/1/2018 00:42 | Tristel cleans up its approach to data with SAP Business One and Codestone SAP Business One Published on 1 Nov 2017 Tristel manufactures infection and contamination control products for medical instruments and surfaces in hospitals, veterinary practices and cosmetic and pharmaceutical companies. Tristel was struggling to consolidate data from multiple branches, which created inconsistencies across the business. It chose SAP Business One for its flexibility, multi-language support and intuitive user interface. Now it can connect all of its entities worldwide, with real-time visibility into operations and finances, which enables head office to be more supportive and collaborative. As Tristel grows and develops new markets and entities, it has confidence that SAP Business One will grow side-by-side. | piedro |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions